Use of trastuzumab for the treatment of early stage breast cancer (Q36573813)

15 August 2017

1 reference

title

Use of trastuzumab for the treatment of early stage breast cancer (English)

1 reference

15 August 2017

1 reference

Sofia Braga

1 reference

15 August 2017

Lissandra dal Lago

1 reference

15 August 2017

Chantal Bernard

1 reference

15 August 2017

Fátima Cardoso

1 reference

15 August 2017

Martine Piccart

1 reference

15 August 2017

publication date

1 August 2006

1 reference

Expert Review of Anticancer Therapy

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

1153-1164

1 reference

EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Amplification of a novel v-erbB-related gene in a human mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Dose scheduling--Herceptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

HER-2 testing in breast cancer using parallel tissue-based methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

CNS metastases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Adjuvant trastuzumab for breast cancer: the other side of the coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

Trastuzumab for early breast cancer: evolution or revolution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1153

10.1586/14737140.6.8.1153

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference